Association Between Use of Thiopurines or Tumor Necrosis Factor Antagonists Alone or in Combination and Risk of Lymphoma in Patients With Inflammatory Bowel Disease.

Related Articles Association Between Use of Thiopurines or Tumor Necrosis Factor Antagonists Alone or in Combination and Risk of Lymphoma in Patients With Inflammatory Bowel Disease. JAMA. 2017 Nov 07;318(17):1679-1686 Authors: Lemaitre M, Kirchgesner J, Rudnichi A, Carrat F, Zureik M, Carbonnel F, Dray-Spira R Abstract Importance: An increased risk of lymphoma has been reported among patients receiving thiopurines for inflammatory bowel disease (IBD). The risk of lymphoma associated with anti-tumor necrosis factor (TNF) agents either alone or in combination with thiopurines is uncertain. Objective: To assess the risk of…

Read More

The risk of non-melanoma skin cancer in New Zealand in Inflammatory Bowel Disease patients treated with thiopurines.

Related Articles The risk of non-melanoma skin cancer in New Zealand in Inflammatory Bowel Disease patients treated with thiopurines. J Gastroenterol Hepatol. 2017 Nov 04;: Authors: Bahi M, Walmsley RS, Gray AR, Young D, Hobbs CE, Aluzaite K, Schultz M Abstract BACKGROUND AND AIM: New Zealand (NZ) has one of the highest rates of non-melanoma skin cancers (NMSC) in the world. Thiopurine use in Inflammatory Bowel Disease (IBD) patients has been shown to increase NMSC risk. This study aimed to investigate the possible increase of NMSC risk in thiopurine-treated IBD…

Read More

Cost-utility Analysis: Thiopurines Plus Endoscopy-guided Biological Step-up Therapy is the Optimal Management of Postoperative Crohn’s Disease.

Cost-utility Analysis: Thiopurines Plus Endoscopy-guided Biological Step-up Therapy is the Optimal Management of Postoperative Crohn’s Disease. Inflamm Bowel Dis. 2017 Oct 09;: Authors: Candia R, Naimark D, Sander B, Nguyen GC Abstract BACKGROUND: Postoperative recurrence of Crohn’s disease is common. This study sought to assess whether the postoperative management should be based on biological therapy alone or combined with thiopurines and whether the therapy should be started immediately after surgery or guided by either endoscopic or clinical recurrence. METHODS: A Markov model was developed to estimate expected health outcomes in…

Read More

A severe neonatal lymphopenia associated with administration of azathioprine to the mother in a context of Crohn’s disease.

A severe neonatal lymphopenia associated with administration of azathioprine to the mother in a context of Crohn’s disease. J Crohns Colitis. 2017 Sep 02;: Authors: Thomas C, Monteil-Ganiere C, Mirallié S, Hémont C, Dert C, Léger A, Joyau C, Caldari D, Audrain M Abstract Azathioprine is commonly used in Crohn’s Diseases. It has been administered to many pregnant women over many years without significant side effects. However, pancytopenia and Severe Combined Immune Deficiency-like disease have been reported in infants whose mothers received azathioprine throughout pregnancy. Moreover, myelotoxicity has been described…

Read More

Prolonged azathioprine treatment reduces the need for surgery in early Crohn’s disease.

Prolonged azathioprine treatment reduces the need for surgery in early Crohn’s disease. J Gastroenterol Hepatol. 2017 Sep 22;: Authors: Qiu Y, Chen BL, Feng R, Zhang SH, He Y, Zeng ZR, Ben-Horin S, Peyrin-Biroulet L, Mao R, Chen MH Abstract BACKGROUND AND AIM: Whether an early use of azathioprine (AZA) can alter the natural history of Crohn’s disease (CD) remains debated. To evaluate the impact of AZA on disease progression in a cohort of patients with early CD. METHODS: This longitudinal cohort study examined patients with early CD defined as…

Read More

Risk factors for thiopurine-induced myelosuppression and infections in inflammatory bowel disease patients with a normal TPMT genotype.

Risk factors for thiopurine-induced myelosuppression and infections in inflammatory bowel disease patients with a normal TPMT genotype. Aliment Pharmacol Ther. 2017 Sep 15;: Authors: Broekman MMTJ, Coenen MJH, Wanten GJ, van Marrewijk CJ, Klungel OH, Verbeek ALM, Hooymans PM, Guchelaar HJ, Scheffer H, Derijks LJJ, Wong DR, de Jong DJ Abstract BACKGROUND: Leucopenia is a common side effect in patients treated with thiopurines. Variants in the thiopurine S-methyltransferase (TPMT) gene are the best-known risk factor, but only explain up to 25% of leucopenia cases. AIM: To identify the clinical risk…

Read More

Screening for Epstein-Barr Virus Status and Risk of Hemophagocytic Lymphohistiocytosis in Children With Inflammatory Bowel Disease on Azathioprine.

Screening for Epstein-Barr Virus Status and Risk of Hemophagocytic Lymphohistiocytosis in Children With Inflammatory Bowel Disease on Azathioprine. Gastroenterology. 2017 Sep 04;: Authors: Chapman S, El-Matary W PMID: 28881189 [PubMed – as supplied by publisher] PubMed Link: https://www.ncbi.nlm.nih.gov/pubmed/28881189?dopt=Abstract

Read More

Thiopurines prevented surgical recurrence in patients with Crohn’s disease after intestinal resection: strategy based on risk stratification.

Related Articles Thiopurines prevented surgical recurrence in patients with Crohn’s disease after intestinal resection: strategy based on risk stratification. J Gastroenterol Hepatol. 2017 Aug 14;: Authors: Guo J, Chen BL, Chen ZH, Luo XP, Qiu Y, Zhang SH, Feng R, He Y, Zeng ZR, Song XM, Ben-Horin S, Mao R, Chen MH Abstract BACKGROUND: Thiopurines (TPs) are effective in reducing risk of clinical and endoscopic recurrence in postoperative patients with Crohn’s disease (CD). However, whether TPs could prevent surgical recurrence (SR) remains unknown. AIM: To explore whether TPs could prevent…

Read More

Thiopurines Dosed to a Therapeutic 6-Thioguanine Level in Combination with Adalimumab Are More Effective Than Subtherapeutic Thiopurine-based Combination Therapy or Adalimumab Monotherapy During Induction and Maintenance in Patients with Long-standing Crohn’s Disease.

Thiopurines Dosed to a Therapeutic 6-Thioguanine Level in Combination with Adalimumab Are More Effective Than Subtherapeutic Thiopurine-based Combination Therapy or Adalimumab Monotherapy During Induction and Maintenance in Patients with Long-standing Crohn’s Disease. Inflamm Bowel Dis. 2017 Aug 03;: Authors: Kariyawasam VC, Ward MG, Blaker PA, Patel KV, Goel R, Sanderson JD, Irving PM Abstract BACKGROUND: The benefit of concomitant immunomodulation with adalimumab (ADA) in Crohn’s disease is poorly understood. We aimed to compare ADA monotherapy with combination therapy with thiopurines, stratified by thioguanine nucleotides (TGNs). METHODS: Retrospective observational study of…

Read More
<< Go Back